Medication Abortion Before Confirmed Intrauterine Pregnancy Noninferior
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 6, 2024 -- For complete abortion, medication abortion before confirmed intrauterine pregnancy is noninferior to standard, delayed treatment, according to a study published in the Nov. 7 issue of the New England Journal of Medicine.
Karin Brandell, M.D., from the Karolinska Institutet in Stockholm, and colleagues conducted a multicenter, noninferiority, randomized controlled trial involving women requesting medication abortion at up to 42 days of gestation with an unconfirmed intrauterine pregnancy on ultrasound examination. Participants were randomly assigned to immediate start of abortion (early-start group; 754 participants) or standard-care treatment delayed until intrauterine pregnancy was confirmed (standard-care group; 750 participants). For the absolute between-group difference, the noninferiority margin was set at 3.0 percentage points.
The researchers found that a complete abortion occurred in 95.2 and 95.3 percent of participants in the early-start and standard groups, respectively (absolute between-group difference, −0.1 percentage points). Ectopic pregnancies occurred in 1.3 and 0.8 percent of participants in the early-start and standard-care groups, respectively. Serious adverse events occurred in 1.6 and 0.7 percent of participants in the early-start and standard groups, respectively, most of which were uncomplicated hospitalizations for ectopic pregnancy or incomplete abortion.
"We found that early start of medication abortion before confirmed intrauterine pregnancy was noninferior to delayed treatment after confirmed intrauterine pregnancy with respect to completing abortion," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-07 12:00
Read more
- UCB Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024
- Autism Diagnoses Rising Among U.S. Children, Adults
- IDSA: 1999 to 2019 Saw Decrease in Sepsis-Related Mortality Rate in Children
- Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
- Vaping Rates Hit Record Lows for U.S. High School Students
- LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions